Related Links Educational Materials About Clinical Trials Clinical Trials: Questions and Answers Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase I/II Study of Donor Natural Killer Cell Infusion After HLA-Mismatched/Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation From a Familial Donor in Patients With Advanced Malignant Disorders

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II, Phase I	Treatment	Active	15 to 75	Other	AMC-UUCM-2008-0383 2008-0383, NCT00823524

Trial Description

Purpose:

Giving an infusion of natural killer cells from a donor after a donor stem cell transplant may help kill any remaining cancer cells after the transplant.

This phase I/II trial is studying the side effects and best dose of donor natural killer cells when given after a donor stem cell transplant in treating patients with advanced cancer.

Eligibility:

Eligibility criteria include the following:

• 15-75 years old
• Has undergone donor stem cell transplant
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Some patients will receive an infusion of natural killer cells twice in week 3.

Other patients will receive an infusion of natural killer cells once in weeks 2 and 3.

After finishing treatment, patients will be evaluated periodically.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Asan Medical Center - University of Ulsan College of Medicine

Kyoo Lee, MD, Principal investigator		Ph: 82-2-2224-3210 Email: khlee2@amc.seoul.kr

Republic of Korea
	Seoul
	Asan Medical Center - University of Ulsan College of Medicine
		Kyoo Lee, MD	Ph:  82-2-2224-3210
			Email: khlee2@amc.seoul.kr

Registry Information
Official Title		Donor NK cell infusion for progression/recurrence of underlying malignant disorders after HLA-haploidentical HCT - a phase 1-2 study
Trial Start Date		2009-01-07
Trial Completion Date		2012-12-31 (estimated)
Registered in ClinicalTrials.gov		NCT00823524
Date Submitted to PDQ		2009-01-07
Information Last Verified		2009-01-13